

16 June 2026

Availability and Rollout Timeline of Fampridine (Fampyra) for Multiple Sclerosis Patients

Please provide the following information regarding the availability, commissioning, and rollout of Fampridine (brand name Fampyra) for eligible Multiple Sclerosis (MS) patients within your Trust for patients residing in or treated within the Belfast Health and Social Care Trust area:

1. Current Availability: Is Fampridine currently available to be routinely prescribed on the NHS to eligible MS patients (meeting the standard EDSS 4–7 criteria) who are under the care of neurologists within the Belfast Trust?

No

2. Patient Numbers: How many patients with a diagnosis of Multiple Sclerosis are currently receiving NHS-funded Fampridine prescriptions within the Belfast Trust?

Less than 5 people

Where numbers are low we have indicated less than 5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.

3. Infrastructure and Clinics: Have specialist assessment or monitoring pathways/clinics required for the initial 2-to-4-week Fampridine walking speed trials been established and staffed in the Belfast and Trust?

No

4. Rollout Timelines: If Fampridine is not yet routinely available or if the necessary clinical assessment infrastructure is not fully operational in Belfast Trust, what is the specific projected timeline or target date for the full rollout and operational availability of this service?

Not yet determined as meetings are ongoing between Trust and SPPG.

5. Interim Funding / Pathways: If routine local pathways are not yet active, what interim processes or Individual Funding Requests (IFRs) are available to eligible patients to access the treatment in the meantime?



16 June 2026

There is a requirement for MDT assessment/prescribing and so the aim is to set up a definitive pathway rather than utilise interim measures.